Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Dan Sorenson who wrote (7414)	11/26/1998 3:05:00 PM
From: Dan Sorenson	Read Replies (1) \| Respond to of 8116

Employee count at 9/30/98 >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>Employees As of September 30, 1998, we employed 109 persons full-time, of whom 11 were engaged in research and development activities, 36 in operations and manufacturing, 23 in clinical and regulatory activities, 18 in administration and management, and 21 in marketing. We believe that it has been successful in attracting skilled and experienced employees; however, competition for such personnel is intense.<<<<<<<<<<<<<, If we get rid of about 40 more of these we will be down to fightin weight, IMO. Dan

To: Dan Sorenson who wrote (7414)	12/8/1998 5:57:00 AM
From: harkenman	Respond to of 8116

Cytogen Gets Expanded Rights To Arthritis Treatment Dow Jones Newswires PRINCETON, N.J. -- Cytogen Corp. (CYTO) acquired an expanded license from Dow Chemical Co. (DOW) for the use of Samarium EDTMP in the treatment of rheumatoid arthritis. In a press release Monday, Cytogen said it gained rights in Europe and Japan to add to its rights in North and Latin America. Dow Chemical makes chemicals, drugs and plastics as well as farming and consumer products. Cytogen is a biopharmaceutical company.